[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659825":3},{"organization":4,"outcomesModule":7,"designInfo":44,"detailedDescription":23,"studyPopulation":47,"armGroups":23,"interventions":23,"overallOfficials":23,"centralContacts":48,"locations":23,"responsibleParty":54,"collaborators":23,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":23,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":23,"studyType":71,"phases":23,"briefSummary":72,"conditions":73,"keywords":23,"overallStatus":80,"whyStopped":23,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":23},{"fullName":5,"class":6},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":23},[9],{"measure":10,"description":11,"timeFrame":12},"Four-point major adverse cardiovascular and cerebrovascular events (4P-MACCE)","The composite of all-cause death, myocardial infarction, stroke, and coronary revascularization.","Assessed at 3, 5, and 10 years.",[14,18,21,24,26,28,30,32,34,36,38,40,42],{"measure":15,"description":16,"timeFrame":17},"Five-point major adverse cardiovascular and cerebrovascular events (5P-MACCE)","The composite of all-cause death, myocardial infarction, stroke, coronary revascularization, and hospitalization for unstable angina","Assessed at 3, 5, and 10 years",{"measure":19,"description":20,"timeFrame":17},"Three-point major adverse cardiovascular events (3P-MACE)","The composite of cardiovascular death, myocardial infarction, and stroke",{"measure":22,"description":23,"timeFrame":17},"Time to first occurrence of all-cause death",null,{"measure":25,"description":23,"timeFrame":17},"Time to first occurrence of cardiovascular death",{"measure":27,"description":23,"timeFrame":17},"Time to first occurrence of myocardial infarction",{"measure":29,"description":23,"timeFrame":17},"Time to first occurrence of stroke",{"measure":31,"description":23,"timeFrame":17},"Time to first occurrence of coronary revascularization",{"measure":33,"description":23,"timeFrame":17},"Time to first hospitalization for unstable angina",{"measure":35,"description":23,"timeFrame":17},"Other cardiovascular hospitalizations",{"measure":37,"description":23,"timeFrame":17},"Quality of life, assessed using the Seattle Angina Questionnaire (SAQ)",{"measure":39,"description":23,"timeFrame":17},"Quality of life, assessed using the 12-Item Short Form Health Survey (SF-12)",{"measure":41,"description":23,"timeFrame":17},"Quality of life, assessed using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L)",{"measure":43,"description":23,"timeFrame":17},"Depressive symptoms, assessed using the Patient Health Questionnaire-9 (PHQ-9)",{"allocation":23,"interventionModel":23,"interventionModelDescription":23,"primaryPurpose":23,"observationalModel":45,"timePerspective":46,"maskingInfo":23},"COHORT","PROSPECTIVE","The study population consists of participants previously enrolled in the TOP-CABG trial who underwent coronary artery bypass grafting (CABG) with at least one saphenous vein graft and were randomized to either 3-month dual antiplatelet therapy or 12-month dual antiplatelet therapy. Participants who completed the original trial and are eligible for extended follow-up will be included to assess long-term graft-related outcomes, cardiovascular events, bleeding events, quality of life, and other patient-reported outcomes.",[49],{"name":50,"role":51,"phone":52,"phoneExt":23,"email":53},"Xin Yuan, MD, PhD","CONTACT","+86 010 60866780","yuanxinfuwai@163.com",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"PRINCIPAL_INVESTIGATOR","Shengshou Hu","Principal Investigator","100659825","top-cabg-trial-follow-up-extension-top-cabg-fe-100659825",false,"NCT07871591","TOP-CABG Trial: Follow-up Extension (TOP-CABG FE)","Extended Follow-up Study of the Efficacy and Safety of De-escalated Antiplatelet Therapy After Coronary Artery Bypass Grafting (TOP-CABG FE)","Inclusion criteria\n\n* Patients 18-80 of age.\n* Patients undergo planned CABG for the first time with ≥1 SVGs\n* Patients with written informed consent.\n\nExclusion criteria\n\n* Concomitant valve (excluding aortic bioprosthesis), aorta, or rhythm surgery during the same session.\n* Patients undergo emergency CABG.\n* Patients with single coronary artery disease.\n* Patients with cardiogenic shock and hemodynamic instability.\n* Patients with sick sinus syndrome, 2nd or 3rd atrioventricular block.\n* Patients with contraindications for coronary computed tomography angiography or coronary angiography (eg. contrast allergy).\n* Use of other antiplatelet drugs than aspirin or ticagrelor (clopidogrel, prasugrel, etc) and unable to discontinue this medication after CABG, in the treating physician's or the investigator's opinion.\n* Patients who take oral anticoagulants before CABG and have to use anticoagulants after surgery.\n* Contraindication for the use of ticagrelor or aspirin (ie. history of bleeding diathesis within 3 months prior presentation, severe gastrointestinal bleeding within 1year prior presentation, peptic ulcer without gastrointestinal bleeding in past 3 years or history of intracranial hemorrhage, allergy, severe gastrointestinal reaction caused by aspirin).\n* Placement of a drug-eluting stent in a coronary or cerebral artery within 6 months of CABG or placement of a bare-metal stent in a coronary or cerebral artery within 1 month of CABG\n* Thrombocytopenia before CABG (\\\u003C 100 x 109\u002FL).\n* Patients with severe renal function impairment requiring dialysis or active liver disease, including patients with unexplained persistent elevated transaminase or any transaminase more than 3 times the normal limit.\n* Use of strong inhibitors of CYP3A4\n* Patients who have to use methotrexate and ibuprofen.\n* Patients with active malignant tumors with increase in bleeding risk in the investigator's opinion\n* Pregnant patients, patients who have given birth within the past 90 days, or who are breastfeeding.\n* Premenopausal women who do not take adequate contraception. Adequate contraception refers to the adoption of at least two reliable methods of contraception, one of which must be a barrier method of contraception.\n* CABG volume of the surgeon less than 50.","ALL","18 Years","80 Years",{"count":69,"type":70},2290,"ESTIMATED","OBSERVATIONAL","To further evaluate the long-term effects of the two antiplatelet strategies on saphenous vein graft patency, long-term adverse cardiovascular events, and bleeding events after coronary artery bypass grafting (CABG), we plan to conduct an extended follow-up study based on the previously completed TOP-CABG trial. This extended follow-up aims to provide high-quality evidence to inform more optimized and individualized long-term antiplatelet management strategies for patients after CABG.",[74,75,76,77,78,79],"Coronary Artery Disease","Coronary Artery Bypass Grafting","Dual Antiplatelet Therapy","Bleeding","Myocardial Ischemia","Myocardial Infarction","NOT_YET_RECRUITING","2026-10-08",{"date":83,"type":84},"2026-10-13","ACTUAL",{"date":86,"type":70},"2026-10-15",{"date":88,"type":70},"2028-06-30",{"name":5,"class":6}]